Canaccord Genuity analyst Sumant Kulkarni maintained a Buy rating on Stoke Therapeutics today and set a price target of $60.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sumant Kulkarni has given his Buy rating due to a combination of factors that, in his view, steadily strengthen the investment case for Stoke Therapeutics. He highlights the advancing Phase 3 EMPEROR trial for zorevunersen in Dravet syndrome, with enrollment completion expected in June and a pivotal data readout targeted for mid-2027, alongside plans to begin a rolling NDA submission in the first quarter of 2027.
He also points to four-year open-label extension data showing durable seizure reduction, cognitive and behavioral gains, and statistically significant improvements in multiple Vineland functional domains, all with a generally favorable long-term safety profile. Combined with a 75% modeled probability of approval, substantial projected peak U.S. sales, additional potential from ex-North America royalties and milestones, and a solid cash position supporting operations into key catalysts, he argues the stock remains undervalued and maintains an unchanged $60 price target.
In another report released today, Needham also maintained a Buy rating on the stock with a $40.00 price target.
Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of STOK in relation to earlier this year.